Ebvallo’s US soap opera plays on
The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
Verastem keeps investors waiting in KRAS
The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
Roche’s phase 1 mystery
Could RO7851624, newly into clinical trials, be RG6735?
BeOne chooses degradation over inhibition
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
Ideaya exits Werner and Pol theta
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
Cytospire’s backers buy in as Pfizer exits
No sooner does one gammadelta-focused biotech die than another takes its place.
